Carisma Therapeutics Announces Changes to its Board of Directors

~ Carisma Therapeutics Inc. (Nasdaq: CARM) has announced the addition of Sohanya Cheng, MBA to their Board of Directors, effective October 31, 2024. The clinical-stage biopharmaceutical company is focused on developing immunotherapies and is excited to have Ms. Cheng join their team.

According to Sanford Zweifach, Chair of the Carisma Board, Ms. Cheng's extensive experience in oncology and her skills in leadership, strategic planning, and commercialization will be valuable assets as the company continues to advance its portfolio and strengthen its foundation.

In addition to Ms. Cheng's appointment, Michael Torok has informed the Board of his intention to step down as a member on October 31, 2024 due to other professional commitments. The Board is grateful for Mr. Torok's service and wishes him well in his future endeavors.

More on EntSun News

• Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
• From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
• AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
• Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
• Peachtree Village International Film Festival (PVIFF) Celebrates 20th Anniversary

Ms. Cheng expressed her enthusiasm for joining Carisma's Board and working with the management team as they strive to deliver innovative immunotherapies to patients facing serious diseases. She looks forward to sharing her insights and supporting the company's strategic goals as it solidifies its position as a leader in engineered macrophages within oncology and beyond.

Carisma Therapeutics Inc. is dedicated to making a positive impact in the field of immunotherapy and is confident that Ms. Cheng's expertise will contribute greatly towards achieving this goal.

---

Show All News | Report Violation